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New Findings: 
• What is the central question of this study? 
Does crosstalk exist between leptin and interleukin-6 in colonic enteric neurons and is 
this a contributory factor in gastrointestinal dysfunction associated with irritable bowel 
syndrome (IBS)? 
• What is the main finding and its importance? 
Leptin ameliorates the pro-secretory and pro-kinetic effects of the pro-inflammatory 
cytokine, interleukin-6 on rat colons. Leptin also suppresses the neurostimulatory effects 
of IBS plasma, which has elevated levels of interleukin-6, on enteric neurons. This may 
indicate a regulatory role for leptin in immune-mediated bowel dysfunction. 
 
 
 
  
Abstract:  
In addition to its role in regulating energy homeostasis, the adipokine, leptin modifies 
gastrointestinal (GI) function. Indeed, leptin-resistant obese humans and leptin-deficient obese 
mice exhibit altered GI motility. In the functional GI disorder, irritable bowel syndrome (IBS), 
circulating leptin levels are reported to differ from healthy controls. Additionally, IBS patients 
display altered cytokine profiles, including elevated circulating levels of the pro-inflammatory 
cytokine, interleukin (IL)-6, which bears structural homology and similarities in intracellular 
signalling to leptin. This study aims to investigate interactions between leptin and IL-6 in colonic 
neurons and their possible contribution to IBS pathophysiology. The functional effects of leptin 
and IL-6 on colonic contractility and absorpto-secretory function were assessed in organ baths 
and Ussing chambers in Sprague Dawley rat colons. Calcium imaging and immunohistochemical 
techniques were employed to investigate the neural regulation of GI function by these signalling 
molecules. Our findings provide a neuromodulatory role for leptin in submucosal neurons, where 
it inhibited the stimulatory effects of IL-6. Functionally, this translated to suppression of IL-6 
evoked potentiation of veratridine-induced secretory currents. Leptin also attenuated IL-6-
induced colonic contractions, although it had little direct effect on myenteric neurons. Calcium 
responses evoked by IBS plasma in both myenteric and submucosal neurons were also 
suppressed by leptin, possibly through interactions with IL-6, which is elevated in IBS plasma. 
As leptin has the capacity to ameliorate the neurostimulatory effects of soluble mediators in IBS 
plasma and modulated IL-6-evoked changes in bowel function, leptin may have a role in 
immune-mediated bowel dysfunction in IBS patients.  
 
 
Abbreviations 
AUC, area under the curve; χ2, Chi squared; CRF, corticotropin-releasing factor; ERK-MAPK, 
extracellular signal regulated kinase-mitogen activated protein kinase; FITC, Fluorescein 
isothiocyanate; GI, gastrointestinal; HC, healthy control; IL, interleukin; IL-6R, interleukin-6 
receptors; IBS, irritable bowel syndrome; IBS-C, constipation-predominant IBS; IBS-D, 
diarrhoea-predominant IBS; IBS-A, alternating IBS; ISC, short circuit current; LMMP, 
longitudinal muscle myenteric plexus; ObR, leptin receptor; PI-3kinase, phosphoinositide 3-
kinase; SMP, sub-mucosal plexus; STAT, signal transducer and activator of transcription, TER, 
transepithelial resistance; TRITC, Tetramethylrhodamine isothiocyanate; TTX, tetrodotoxin; 
xleptin, monoclonal leptin antibodies. 
  
Introduction 
Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal (GI) disorder, 
affecting approximately 15-20% of the worldwide population (Lovell & Ford, 2012). 
Characterized by episodes of abdominal pain, bloating and altered bowel habit (Longstreth et al., 
2006), IBS severely impinges on the quality of life of sufferers and confers a heavy economic 
and societal burden (Nellesen et al., 2013). Symptoms vary amongst patients with constipation-
predominant (IBS-C), diarrhoea-predominant (IBS-D) or alternating (IBS-A) subtypes (Yale et 
al., 2008). Such heterogeneity in symptom phenotype, in addition to the absence of reproducible 
biomarkers and a lack of clarity on the underlying pathophysiology all hamper the search for 
effective treatments. 
 
A number of factors are thought to contribute to the initiation, persistence and severity of IBS 
symptoms, including stress (Folks, 2004) and immune activation (Quigley, 2006; Elsenbruch, 
2011; O'Malley et al., 2011b), with evidence of elevated levels of pro-inflammatory cytokines 
such as interleukin (IL)-6 and IL-8 (Dinan et al., 2006; Liebregts et al., 2007; Dinan et al., 2008; 
McKernan et al., 2011) and an altered IL-10/IL-12 ratio (O'Mahony et al., 2005). Such changes 
in cytokine profile indicate a pro-inflammatory state in IBS patients, although not all studies 
have detected these immune changes in the circulation or mucosa (Chang et al., 2012). 
Observations that soluble mediators, both secreted by IBS mucosal biopsies (Buhner et al., 2009) 
and in IBS plasma (O'Malley et al., 2011a; Buckley et al., 2014) have functional effects in the 
gut suggest that cytokines, hormones and enzymes have a role in the pathophysiology of IBS. 
Supernatants containing histamine, serotonin and proteases from both IBS-C and IBS-D patients 
activate human enteric neurons (Buhner et al., 2009) and IL-6 and corticotropin-releasing factor 
(CRF) in IBS plasma modulate enteric neurons resulting in altered bowel contractile and 
absorpto-secretory function.  
 
Another circulating factor with neuromodulatory actions is leptin, an adipokine secreted by white 
fat cells and gastric secretory cells. Leptin has important effects on satiety and energy 
homeostasis but also plays a role in GI function, as obese humans (Gallagher et al., 2007) and 
leptin-deficient obese mice (Kiely et al., 2005) exhibit altered gut motility. However, the effects 
of leptin may be dependent on the source. If leptin is secreted from gastric secretory cells, it may 
engage with leptin receptors (ObRs) on the luminal border of intestinal cells. Luminally-secreted 
leptin can modify nutrient uptake in the small intestine but has also been characterized as a pro-
inflammatory cytokine, contributing to barrier breakdown and inflammation (Sitaraman et al., 
2004) and causing upregulation of pro-inflammatory cytokines such as IL-6 (Padidar et al., 
2011). If it originates from adipocytes, leptin may bind to ObRs on the basolateral surface of 
epithelial cells or on enteric neurons (Liu et al., 1999). Indeed, leptin can activate both 
submucosal and myenteric neurons (Reichardt et al., 2011), which regulate absorpto-secretory 
function and motility, respectively. A recent study demonstrated a neuroprotective effect of diet-
induced obesity on the enteric nervous system that is likely to involve leptin (Baudry et al., 
2012). Serum leptin has been reported to be reduced in IBS patients, independent of factors such 
as IBS sub-type, body mass index or stress levels (Semnani et al., 2009), although others have 
found that it was elevated in IBS-D plasma (Russo et al., 2013). This study will examine the 
cellular and functional effects of interactions between leptin and IL-6 in the context of the 
functional bowel disorder, IBS. 
 
Materials and Methods 
Ethical Approval 
The study protocol (APC020, 2009), for collecting blood samples form IBS patients and healthy 
volunteers was approved by the University College Cork Clinical Research Ethics committee of 
the Cork University Hospital in accordance with the Declaration of Helsinki. Written informed 
consent was obtained from all participants. All animal experiments were in full accordance with 
the European Community Council Directive (86/609/EEC) and the local University College 
Cork Animal Experimentation Ethics Committee. 
 
Animals and Tissue collecting 
Male Sprague Dawley rats (8-12 weeks old) purchased from Envigo, Derbyshire, UK, were 
group-housed 6 per cage and maintained on a 12/12 hour dark-light cycle (08.00-20.00) with a 
room temperature of 22±1oC. Animals were permitted at least one week to acclimatize to their 
new environment prior to experimentation. Food and water were available ad libitum. Rats were 
sacrificed using CO2 and decapitation. A section of the colon was excised from each rat, cut 8cm 
proximal to the anus. The excised distal colon was stored in ice-cold Krebs saline (pH7.4), 
containing in mmolL-1: 117 NaCl, 4.8 KCl, 2.5 CaCl2, 1.2 MgCl2, 25 NaHCO3, 1.2 NaH2PO4 and 
11 D-glucose.  
 
As previously reported (McKernan et al., 2011), human plasma was collected from healthy 
controls and IBS patients. IBS patients were aged 18–65 years and satisfied Rome II criteria for 
the diagnosis of IBS, with recurrent abdominal pain or discomfort for at least 3 days per month 
in last 3 months. Additionally, patients recruited from gastroenterology clinics at Cork 
University Hospital, Cork, Ireland had two or more of the following symptoms: improvement 
with defecation, onset associated with a change in frequency of stool or onset associated with a 
change in form of stool. According to Rome II sub-classifications bowel habit was defined as 
constipation-predominant (IBS-C), diarrhoea-predominant (IBS-D) or alternating (IBS-A) 
subtypes. Healthy controls were recruited from hospital staff or the research institute (UCC). 
Individuals with a history of psychiatric illness, inflammatory bowel disease, coeliac disease, 
lactose intolerance, immunodeficiency or abdominal surgery were excluded. No patient was 
categorized as having post-infectious IBS. Alternative diagnoses were ruled out based on clinical 
history, physical examination, laboratory tests, imaging and endoscopy, as appropriate. Each 
individual was evaluated with a full review of their family history, details of current and recent 
medications, a physical examination and documentation of body mass index. All patients had 
active IBS, however disease activity was not used as a discriminatory factor, only IBS subtype. 
None of the controls were taking any medications (contraception excluded). Most IBS patients 
(17/18) were being treated with laxatives, antispasmodics, anti-peristaltic drugs, antidepressants, 
contraceptives or hormone replacement therapy.  
 
20ml of venous blood was donated between 11:00 and 13:00 h to avoid diurnal variations. Whole 
blood (15 ml) was added to an equal volume of Histopaque 1077 (Sigma, St. Louis, MO, USA) 
and centrifuged at 400g (30 min, room temperature). Plasma was collected and stored at -80oC. 
A subset of plasma samples (n = 6 samples from each group) from both healthy volunteers and 
IBS patients (2 IBS-D, 2 IBS-C and 2 IBS-A) were randomly selected from a larger previously 
published study (McKernan et al., 2011).  
 
Calcium Imaging 
For calcium imaging studies, whole mount preparations of myenteric and submucosal plexus 
were prepared from the distal colon of healthy Sprague Dawley rats. The colon was kept whole 
and mounted on a glass rod, where the outer serosal layer was scored lightly with a blade along 
the mesenteric border. Using a damp cotton swab, the outer serosa was removed. The colonic 
tissue (~2cm x 2cm) was subsequently pinned out in Sylgard-lined dishes and the mucosa 
removed. For myenteric preparations, the mucosa was removed, the tissue was turned over and 
the circular muscle was removed using forceps to leave longitudinal muscle and myenteric 
neurons. Enteric neuronal preparations were loaded with Fura-2AM (7μM, 1 hr) in Krebs saline 
solution prior to imaging. Cell R software (Olympus Soft imaging solutions, 1986-2009) was 
used to record excitation changes in intracellular calcium (O'Malley et al., 2011a). Images were 
acquired at 3Hz using a Xenon/Mercury arc burner (Olympus, Melville, NY, US), a charge-
coupled device digital camera (F-view II, Soft imaging system, Munster, Germany) and a 40x 
water-immersion objective on a fixed stage upright microscope (Olympus BX51WI). Ganglionic 
neurons were retrospectively identified based on morphology and responsivity to brief 
application of 75mM KCl at the end of the recording protocol. Responding neurons were defined 
as those with increases in intracellular calcium [Ca2+]i greater than two standard deviations from 
baseline (calculated as the average ratio during the 150 seconds preceding stimulus application). 
Reagents were applied in random order to avoid run-down of calcium stores being a confounding 
factor. A perfusion system continuously superfused the colonic tissue with carbogen-bubbled 
Krebs-buffered saline at room temperature. Nifedipine (1μM), which is a potent inhibitor of 
calcium channels in smooth muscle, was continuously present in the perfusate to inhibit smooth 
muscle contractions.  
 Immunofluorescence of whole mount preparations 
Whole-mount preparations were fixed in Zamboni's fixative (4oC, overnight), permeabilised with 
0.1% Triton X-100 and blocked with 1% donkey serum. Sub-mucosal plexus (SMP) and 
longitudinal muscle myenteric plexus (LMMP) tissue preparations were incubated with 
antibodies against leptin or IL-6 (1:100 @ 4oC overnight), leptin receptors (ObR, 1:300 @ 4oC 
overnight), interleukin-6 receptors (IL-6R, 1:300 @ 4oC overnight) or cFos (1:100 @ 4oC 
overnight, all procured from Santa Cruz Biotechnology, Dallas, TX, USA) and the associated 
FITC (Fluorescein isothiocyanate) - or TRITC (Tetramethylrhodamine isothiocyanate)  - 
conjugated secondary antibodies (1:250, incubated at room temperature for 2 hours, Jackson 
Immunoresearch, Westgrove, PA, USA). Images were captured using Olympus D71 upright 
fluorescent microscope and Cell F software (Soft Imaging Solutions) or a FVlOi-Olympus-
confocal microscope with Fluoview software. Control experiments detected no non-specific 
fluorescence when the FITC - and TRITC - conjugated secondary antibodies were incubated in 
the absence of primary antibodies. Similarly, no fluorescence was detected on neurons when 
anti-ObR and anti-IL-6R antibodies were applied to the neurons in the absence of secondary 
fluorophores.  
 
Organ baths  
The distal colon was excised from Sprague Dawley rats, the mucosa removed and the tissue was 
orientated transversely or longitudinally to measure circular or longitudinal muscle contractility, 
respectively. The colonic tissue was suspended from a tension transducer in a tissue bath of 
carbogen-bubbled Krebs saline under 1g of tension and allowed to equilibrate (20 – 30 minutes) 
before reagents were added to the bath. Changes in tension were recorded and analysed using 
Powerlab and LabChart7 (AD instruments Inc, Colorado Springs, CO, US). Responses are 
reported as a percentage of the maximal response evoked by the cholinergic agonist, carbachol 
(100µM), in each experiment. The tissue was exposed to carbachol at the start and end of the 
experiment and no deterioration in the contractile response was noted. Reagents were added to 
bath at the final concentration. Before the addition of the next reagent, the bath was flushed twice 
with Krebs saline and the no further reagents were added until the baseline was restored (~20 
minutes). 
 
Ussing chambers  
Mucosa–submucosa preparations were mounted in Ussing chambers (exposed area of 0.12 cm2) 
with 5 ml of Krebs solution (95% O2/5% CO2, 37oC) in both the basolateral and luminal 
reservoirs. Tissues were voltage-clamped at 0 mV using an automatic voltage clamp (EVC 4000, 
World Precision Instruments, Sarasota, Florida, US) and the short-circuit current (Isc) required to 
maintain the potential at 0 mV was monitored as a reflection of the net active ion transport across 
the epithelium. Resistance was calculated using Ohms law. Experiments were carried out 
simultaneously in chambers connected to a PC equipped with DataTrax II software (World 
Precision Instruments). Following mounting, tissue was allowed to equilibrate (~ 1 hour) until a 
stable baseline was achieved. Reagents were added to the basolateral chamber. 
  
Statistical Analyses  
Data was analysed using GraphPad prism for windows (version 7). The data are represented as 
mean values ± the standard error of the mean. Assuming a null hypothesis, Students’ or paired t-
tests were used when comparing two groups and repeated measures ANOVA with Bonferroni’s 
multiple comparison post-hoc test were used when comparing more than two groups. Chi 
squared (χ2) tests were used to compare percentages. P≤0.05 was considered significant. 
 
 
Results: 
Leptin has neurostimulatory effects in submucosal but not myenteric neurons. 
Locally secreted leptin could have neurostimulatory effects on colonic neurons. Thus, 
submucosal and myenteric neurons were investigated to determine if leptin could induce 
signalling in this region. Fixed preparations of submucosal ganglia from healthy rat colons 
displayed abundant, cytosolic expression of both leptin protein and ObRs (figures 1A and 1B). 
Dual-labelling of SMP tissue preparations for leptin and IL-6 displayed significant co-
localization. Expression of both proteins was punctate and concentrated in the neuronal cytosol 
and at the cell membrane. Quantification of neurons determined that 79% of neurons expressing 
IL-6 also expressed leptin (n=39 neurons from n=9 ganglia from 3 rats, figure 1A). Expression of 
IL-6Rs and ObRs was also prevalent in submucosal neurons, however only 14% of neurons were 
found to co-express both receptors (n=32 neurons from 9 ganglia from 3 rats, figure 1B). 
Calcium imaging studies demonstrated that exposure of submucosal neurons to leptin resulted in 
an increase in intracellular calcium. A dose-response curve for leptin in SMP neurons revealed 
robust but short-lived increases in intracellular calcium which increased in amplitude in a 
concentration dependent manner from 10pM to 1nM (each applied for 3 minutes). No further 
increase in amplitude was noted by application of 10nM leptin so 1nM recombinant leptin was 
used for the remainder of the calcium imaging experiments (figure 1C). At this concentration, 
leptin activated 17% of submucosal neurons responsive to high K+ whereas we previously 
observed that ~43% of neurons are excited by IL-6 (O'Malley et al., 2011a). Sequential addition 
of 1nM leptin evoked reproducible calcium responses (0.04 ±0.004 vs 0.03 ±0.004 vs 0.04 
±0.01, n=24 neurons, p>0.05, repeated-measures ANOVA). With evidence of IL-6R and ObR 
co-localization in submucosal neurons, calcium imaging was used to confirm that the same 
submucosal neurons responded to both leptin and IL-6 and to assess potential crosstalk between 
the adipokine and cytokine. Recombinant leptin (1nM, 3 min) evoked a calcium response of 
equivalent amplitude to the calcium influx stimulated by IL-6 (1nM, 3 min, p>0.05, n=24 
neurons from 3 rats). However, it was interesting to note that the application of both IL-6 and 
leptin together induced a response of smaller amplitude than leptin alone (p<0.05, figure 1D), 
indicating potential interactions between these neuromodulatory reagents. 
 
Leptin activates JAK-STAT signalling cascades in submucosal neurons. 
Given neurostimulatory effects of leptin in submucosal neurons, further calcium imaging studies 
were carried out in the SMP to determine the intracellular mechanisms underlying this action. 
The neurotoxin, tetrodotoxin (TTX, 100nM, 20min) resulted in just a small decrease in 
amplitude of the leptin-induced response (n=34, p<0.001), revealing a considerable TTX-
insensitive component (figure 2A). In terms of intracellular signalling molecules, a signal 
transducer and activator of transcription (STAT) 3-specific pharmacological inhibitor, WP1006 
(10µM, 20min), which had no effect on calcium levels per se, attenuated the leptin-evoked 
response (n=31, p<0.001). The smaller neuronal response to leptin and IL-6 together (p<0.001), 
was unchanged in the presence of WP1006 (p>0.05, figure 2B). Interestingly, inhibition of the PI 
3-kinse signalling pathway with wortmannin (10µM, 20min) which had no effect on [Ca2+]i, 
potentiated the leptin-evoked response in submucosal neurons (n=25, p<0.001). However, the 
smaller amplitude response to leptin and IL-6 together (p<0.05) was not further changed by 
wortmannin (n=27, p>0.05, figure 2C). The ERK-MAPK inhibitor, PD98059 (10µM, 30min) 
had no effect on [Ca2+]i nor the leptin-evoked calcium response (n=22, p>0.05). The suppressed 
calcium response of leptin in the presence of IL-6 was also unaffected by PD98059 (n=32, 
p>0.05, figure 2D).  
 
Leptin does not stimulate colonic absorpto-secretory function 
As submucosal neurons are important in the regulation of colonic absorption and secretion, 
Ussing chambers were used to determine if leptin had an impact on absorptive or secretory 
function in healthy rat colons. Given that levels of IL-6 are elevated in the plasma of IBS patients 
(Dinan et al., 2006; Liebregts et al., 2007; Dinan et al., 2008; McKernan et al., 2011), blood 
vessels feeding the basolateral side of the colon are the likely site of action for this cytokine. 
Leptin secreted locally by adipocytes are also likely to interact with this side of the mucosal 
barrier. Hence, both exogenous leptin and IL-6 and other pharmacological reagents were added 
to the basolateral Ussing chamber. Short circuit current (ISC) measurements were used as an 
indicator of ionic movement across colonic tissue and transepithelial resistance (TER) as an 
indicator of gut permeability. Similar to previous findings (O'Malley et al., 2013) the relative 
change in TER over the course of the experiment increased in tissues stimulated with IL-6 (22.8 
±2.9 Ω/cm2, p<0.01 compared to the start of the experiment), whereas saline-treated control 
preparations showed no change (n = 8, p>0.05). Leptin didn’t evoke any change in TER over the 
course of the experiment (n=8, p>0.05). However, tissue incubated with both IL-6 & leptin 
showed an increase in TER (n=8, 17.9±2.4 Ωcm-2, p<0.01, figure 3A) that was not different to 
the change in resistance evoked by IL-6 alone (p>0.05, ANOVA comparing TER at the end of 
the experiment).  
 
Fifteen minutes after the addition of leptin (1nM) a small increase in ISC was recorded but this 
didn’t reach significance (p>0.05, n=9). As previously reported (O'Malley et al., 2011a), IL-6 
stimulated a small increase in basal current (p<0.05, n=8) and this was unaffected by the 
presence of leptin (n=8, p>0.05, figure 3B). We have earlier demonstrated that IL-6-evoked 
calcium responses in submucosal neuron are inhibited by TTX. Moreover IL-6 potentiates 
currents induced by the Na+ channel activator, veratridine (O'Malley et al., 2011a). We 
reconfirmed the importance of neural regulation in the IL-6-evoked modulation of absorpto-
secretory function (n=8, p<0.01) but found no such effect with leptin, which didn’t potentiate 
veratridine- (10µM, 15 minutes) evoked secretory currents (n=8, p>0.05). However, 
interestingly, leptin did suppress the stimulatory actions of IL-6 on the veratridine-evoked 
current (n=8, p<0.05, figure 3C).  
 
To assess the role of the parasympathetic neurotransmitter acetylcholine, in colonic secretion, the 
ISC evoked by the cholinergic agonist, carbachol (10µM, 15 min) was compared under basal 
conditions and in the presence of leptin, IL-6 and IL-6 & leptin. We previously observed IL-6-
mediated enhancement of a current evoked by bethanechol, another cholinergic agonist 
(O'Malley et al., 2011a), and in these studies IL-6 similarly potentiated the carbachol-evoked 
cholinergic current (n=8, p<0.05) whereas leptin had no effect on cholinergic secretion per se 
(n=8, p>0.05), nor did it affect the capacity of IL-6 to potentiate secretion (n=8, p<0.01, figure 
3D). Finally, the effects of leptin on capsaicin-evoked colonic currents were assessed. This 
sensory nerve stimulant (1μM, 15 minutes) evokes a biphasic change in ISC with a small 
secretory response followed by a larger and more sustained anti-secretory current. Consistent 
with previous findings (O'Malley et al., 2011a), IL-6 did not significantly alter this current in 
either of the phases (n=8, p>0.05). Exposure of the basolateral colonic surface to leptin had no 
impact on the current evoked by capsaicin, which was similar to the control response (n=8, 
p>0.05). Similarly, the capsaicin-evoked current in the presence of leptin and IL-6 was not 
significantly different to the control (n=8, p>0.05, figure 3E). 
 
Leptin modulates IL-6 mediated increases in colonic contractility 
We have previously determined that IL-6-evoked colonic contractions are mediated via direct 
effects on smooth muscle and also via activation of enteric neurons (Buckley et al., 2014). 
Immunofluorescent staining of myenteric ganglia displayed weak expression of ObRs in 
comparison to strong expression of IL-6Rs in the same neurons (n=4, figure 4A). Consistent with 
these expression levels, IL-6 (1nM, 3 min) evoked robust calcium responses in myenteric 
neurons whereas the change in intracellular calcium evoked by leptin was negligible. Co-
application of leptin and IL-6 resulted in a calcium response similar to that evoked by IL-6 alone 
(p>0.05, figure 4B).  
In organ baths, addition of carbachol (100µM) at the beginning and end of the experiment 
demonstrated that evoked contractions in the distal colon were not diminished over time (p>0.05, 
n=5, data not shown). When colonic samples were suspended to measure circular muscle 
activity, we found that both the amplitude (0.3 ±0.01 vs 0.8 ±0.2 milli Newtons (mN), p<0.05) 
and frequency (0.009 ±0.001 vs 0.2 ±0.03 contractions/minute, p<0.05) of contractions was 
enhanced when leptin (1nM) was added to the organ bath. The area under the curve (AUC) was 
also measured as an assessment of the total response (n=5, figure 4C). The stimulatory effects of 
leptin on circular muscle contractile activity was smaller than contractions evoked by IL-6 both 
in amplitude (4.0 ± 1.0 mN, p<0.05) and frequency (1.39 ±0.45 contractions per minute, n=5, 
p<0.05). However, application of IL-6 to the bath caused a notable decrease in colonic tone 
(decrease of 2.0 ±0.2 mN, noted in 4/5 colonic strips) in circular muscle tissue preparations. 
Interestingly, addition of leptin and IL-6 together, resulted in some recovery of colonic tone 
(increase of 3.0 ±1.0 mN, n=5, p<0.01), but suppressed the generation of distinctive colonic 
contractions as compared to control IL-6 effects (n=5, p<0.01 figure 4C).  
 
Overall, contractions evoked in longitudinal muscle were of smaller amplitude than those 
observed for circular muscle, but continuous contractions were frequently seen in unstimulated 
tissue. Leptin evoked contractions of increased amplitude (0.15 ±0.04 mN) and frequency (0.48 
±0.09 contractions/min, n=5) as compared to baseline values of 0.09 ±0.01 mN and 0.11 ±0.03 
contractions/min (p<0.05) in longitudinal muscle. However, the contractile activity stimulated by 
IL-6 was also of larger amplitude (1.0 ±0.3 mN), frequency (1.32 ±0.45 contractions per minute) 
and AUC than that evoked by leptin (p<0.05), although no change in tone was observed. The IL-
6-evoked response was suppressed when leptin was also added to the bath (p<0.05, figure 4D) 
similar to the effect seen in circular muscle. 
  
Tetrodotoxin (TTX, 100nM, 20min) had little effect on the stimulatory actions of leptin on either 
circular (n=3, p<0.05, figure 4E) or longitudinal (n=3, p<0.05, figure 4F) muscle contractile 
activity indicating that the leptin-mediated excitation of colonic contractility is not likely to be 
neurally-mediated and is probably due to direct effects on smooth muscle. This is consistent with 
the observation that leptin had minimal neuroexcitatory effects on myenteric neurons, which are 
the primary regulators of colonic motility with no further change in calcium levels noted in the 
presence of TTX (change in ratio: 0.003 ±0.002 vs 0.01 ±0.01, n=23, p>0.05). 
 
Leptin attenuates calcium responses evoked by soluble mediators in IBS plasma. 
Although leptin levels are undetermined in these samples, a previously published report using 
these samples found no difference in body mass index between healthy controls and IBS 
patients, which were both in the healthy weight range (McKernan et al., 2011). To minimize 
variability in responses, a pooled sample of plasma from 6 IBS patients representing each of the 
IBS subtypes, was used to investigate the importance of leptin in the neuromodulatory effects of 
IBS plasma. In immunofluorescent studies, exposure of submucosal neurons to IBS plasma 
(1:250 dilution, 15 minutes) resulted in nuclear expression of the cFos early transgene in 51% of 
leptin immunopositive submucosal neurons. By comparison only 37% of submucosal neurons 
exposed to plasma from healthy controls (HCs, 1:250 dilution, 15 minutes) expressed nuclear 
cFos staining in leptin-expressing neurons (p<0.01, χ2 = 8.4, figure 5A).  
 
We have previously found that IBS plasma evokes robust increases in calcium in both enteric 
neuronal plexi whereas healthy plasma is not neurostimulatory, effects mediated in part by 
interleukins and CRF (Buckley et al., 2014; O'Malley et al., 2015). In the current studies, IBS 
plasma similarly evoked robust calcium responses in 38% of myenteric and 27% of submucosal 
neurons tested. To mimic elevated leptin levels, which would be characteristic of obesity and 
may have neuro-protective effects in the enteric nervous system (Baudry et al., 2012), 
recombinant leptin (1nM) was added to the sample of pooled IBS plasma prior to application. A 
smaller calcium response was evoked in both submucosal (p<0.05, figure 5B) and even 
myenteric (p<0.001, figure 5C) neurons when leptin levels were elevated, as compared to control 
IBS plasma responses.  
 
In the submucosal plexus, 27% (n=26/98) of neurons were activated by IBS plasma. When IBS 
plasma was incubated with leptin, only 14% (n=14/98) of neurons were activated. Of the 26 
neurons activated by IBS plasma, 17 (65%) were inhibited and 9 (35%) were insensitive to the 
effects of leptin. Similarly, other submucosal neurons, not initially activated by IBS plasma, 
were activated when leptin was co-applied. While 38% (n=45/118) of myenteric neurons were 
stimulated by IBS plasma, only 18% (n=21/118) of neurons responded to IBS plasma when 
leptin was co-applied. Thus, the decrease in mean amplitude of the calcium responses was due to 
two contrasting effects of leptin. Of the 45 myenteric neurons activated by IBS plasma, 30 (67%) 
were inhibited by leptin whereas 15 (33%) were not sensitive to the inhibitory effects of leptin. 
Another subgroup of neurons not initially activated by IBS plasma, were activated by the 
addition of leptin.  
 
Complimentary studies found that prior incubation of the IBS plasma sample with antibodies 
against leptin (xleptin), to bind and inactivate any endogenous leptin present in the plasma, 
potentiated the response evoked by IBS plasma in both myenteric (n=46, p<0.001) and 
submucosal (n=26, p<0.05, figure 5D) neurons.   
 
  
Discussion 
Previous studies demonstrated that leptin, an adipokine with modulatory effects on bowel 
function (El Homsi et al., 2007; Reichardt et al., 2011), increases neuronal firing in both 
submucosal and myenteric neurons in the guinea-pig colon, an effect that was more pronounced 
in the submucosal plexus (Reichardt et al., 2011). On the whole, our data concur with these 
findings, with leptin stimulating increased neuro-excitability in submucosal neurons from rat 
colons with little or no responses generated in myenteric neurons. Similar to a report that failed 
to see functional effects of leptin in contractility or secretion (Reichardt et al., 2011), our studies 
did not find that leptin directly stimulated colonic secretion or contractile activity. However, 
Reichardt et al  proposed that leptin exerts subtle effects in the colon, that are likely to alter 
function only in concert with other mediators (Reichardt et al., 2011) and indeed, we have shown 
that leptin can modify the pro-secretory and pro-kinetic effects of the pro-inflammatory cytokine, 
IL-6 on colonic function. Intriguingly, leptin suppressed the neuro-stimulatory effects of IBS 
plasma, which has elevated levels of IL-6, in both submucosal and myenteric neurons, indicating 
a possible role for leptin in ameliorating the unfavourable effects of pro-inflammatory cytokines 
in GI dysfunction associated with IBS.   
 
An Iranian study with 80 IBS patients and 80 controls found that leptin levels are lower in IBS 
plasma (Semnani et al., 2009), suggesting a possible role for leptin in the pathophysiology of the 
disorder. That said, another group comparing diarrhoea-predominant IBS patients with healthy 
controls and those with coeliac disease noted elevations in both leptin and IL-6 in the IBS-D 
group (Russo et al., 2013). In our studies, soluble mediators present in IBS plasma stimulated 
more cFos activation in leptin-containing submucosal neurons that healthy control plasma. 
Although leptin levels are unknown in these samples, the patients had comparable body mass 
indices (McKernan et al., 2011). As we have previously shown that IBS secretory products, 
which include cytokines and CRF, potentiate neuronal excitability in enteric neurons (O'Malley 
et al., 2011a; O'Malley et al., 2012; Buckley et al., 2014), it was interesting to note in the current 
studies that artificially increasing leptin levels in IBS plasma ameliorated the neuro-excitatory 
effects in both myenteric and submucosal neurons. The regulatory role of leptin was further 
confirmed by neutralizing leptin present in IBS plasma using an antibody against the leptin 
protein, which resulted in potentiation of the calcium responses in both myenteric and 
submucosal neurons. Although these results are consistent with a study that demonstrated that 
elevated levels of circulating leptin is neuroprotective in the enteric nervous system (Baudry et 
al., 2012), the mechanism by which leptin can modulate the amplitude of calcium response in 
these neuronal plexi requires further investigation. This is particularly true in the myenteric 
neurons, which showed minimal expression of ObRs and responsivity to recombinant leptin. The 
effects of leptin on gut function are complex, as confirmed by a study in rats which found that 
two groups of vagal afferent nerve endings innervated the stomach, one group is leptin-sensitive 
and stimulates motility, whereas a second group is leptin-insensitive and inhibits motility (Wang 
et al., 1997). We similarly noted two groups of neurons that were either sensitive or insensitive 
to leptin. In both myenteric and submucosal neurons, approximately two thirds of neurons 
excited by IBS plasma became quiescent when leptin was co-applied, with the remainder being 
insensitive to leptin.  
 
The source of leptin may be important (Hanani et al., 2007), but whether leptin stimulates the gut 
from the luminal side, acting in a manner similar to pro-inflammatory cytokines (Sitaraman et 
al., 2004) or from the adipocytes, where diet-induced obesity is related to increased colonic 
transit with concurrent increases in both leptin and IL-6 levels (Reichardt et al., 2013), it is 
apparent that a relationship exists between leptin and IL-6. Indeed, leptin induces upregulation of 
pro-inflammatory cytokines, such as IL-6, in colonic cells (Padidar et al., 2011) and ObR and IL-
6R signalling cascades exhibit significant homology. Both activate signalling cascades involving 
JAK-STAT (Bjorbaek & Kahn, 2004), PI 3-kinase (Shanley et al., 2002) and MAPK (Cui et al., 
2006). Our studies found that the JAK-STAT nuclear transcription activating pathway was key to 
the neurostimulatory effects of leptin in submucosal neurons. Interestingly, PI 3-kinase, which is 
an important neuronal signalling molecule that regulates cellular differentiation, growth, survival 
and intracellular trafficking, appeared to be a negative regulator of leptin-evoked neuronal 
stimulation as wortmannin potentiated leptin-evoked stimulation of submucosal neurons. ERK-
MAPK signalling did not appear to mediate the neuro-excitatory effects of leptin in either the 
absence or presence of IL-6. These observations suggest that activation of leptin receptors in 
submucosal neurons evokes calcium responses mediated by JAK-STAT signalling. The 
suppression of the leptin response in the presence of IL-6 was unchanged by the STAT3 inhibitor 
but this may reflect a floor effect. PI-3 kinase appears to negatively regulate the leptin evoked 
response but didn’t affect the calcium response evoked by combined application of IL-6 and 
leptin. Potential crosstalk between leptin and IL-6 was indicated by suppression of the leptin-
evoked calcium response when both leptin and IL-6 were applied to the neurons at the same 
time. However, it is not clear at which point in the cellular signalling cascades this crosstalk 
occurs as the calcium response to leptin and IL-6 together was unaffected by any of the 
inhibitors. Though the leptin-evoked calcium response in submucosal neurons was mediated in 
part by TTX-sensitive Na+ channels, a significant component of the rise in neuronal calcium 
levels was due to mechanisms which did not involve voltage gated Na+ channels, or perhaps 
utilized TTX-insensitive Na+ channels (Yoshida, 1994).  
 
To determine if the neuro-stimulatory effects of leptin on submucosal neurons resulted in 
functional changes in gut barrier permeability and ionic movement across the mucosa, changes in 
TER were measured. Consistent with previous studies (Wang et al., 2007; O'Malley et al., 2012), 
IL-6 evoked an increase in TER, indicating that acute exposure to this pro-inflammatory 
cytokine helps to maintain the integrity of the gut barrier. Leptin has previously been observed to 
contribute to barrier breakdown and inflammation (Sitaraman et al., 2004); however, these 
effects are thought to be mediated from the luminal side. Application of leptin to the basolateral 
side of the colonic tissue had no effect on TER over the observed period, nor did leptin influence 
the protective effects of IL-6. Indeed, leptin-deficient ob/ob mice do not display changes in gut 
permeability (Stenman et al., 2013). Similar to previous observations (O'Malley et al., 2012) and 
consistent with the neurostimulatory effects of IL-6 on submucosal neurons, a small secretory 
current was evoked by IL-6. However, despite the neuroexcitatory effects of leptin in 
submucosal neurons, no changes in ISC were noted, which is consistent with previous reports 
(Reichardt et al., 2011), nor did leptin alter the current evoked by IL-6. Moreover, while IL-6 
potentiated the neurally-mediated secretory current evoked by the Na+ channel agonist, 
veratridine and the cholinergically-mediated current evoked by carbachol, leptin had no effect on 
these currents nor the biphasic current evoked by capsaicin, a TRPV1 agonist which activates 
visceral afferent neurons to stimulate mucosal electrolyte transport and fluid secretion (Vanner & 
MacNaughton, 1995). When the tissue was exposed to IL-6 in the presence of leptin, no change 
was noted in the capacity of IL-6 to directly evoke a secretory current. However, leptin did 
attenuate the IL-6-mediated enhancement of the veratridine-evoked current, although it had no 
effect of the carbachol-evoked current. When considering this result in the context of the calcium 
responses in submucosal neurons, it may be that leptin-sensitive and leptin-insensitive neurons 
underlie changes in secretion. Given the lack of effect of leptin on the IL-6-evoked potentiation 
of the carbachol current, it may indicate that cholinergic neurons in the submucosal ganglia are 
insensitive to leptin, although further investigation is required to confirm this.  
 
In terms of colonic contractility, we have previously reported the stimulatory actions of IL-6 on 
both circular and longitudinal colonic muscle (Buckley et al., 2014), an effect that was mediated, 
at least in part, by myenteric neurons. Leptin also stimulated increased contractile activity, 
although this was smaller in amplitude than the IL-6 effect. Interestingly, when both leptin and 
IL-6 were added together, leptin suppressed the IL-6-evoked contractile activity. This was noted 
in both circular and longitudinal muscle layers and indicates likely cellular crosstalk between the 
factors. While myenteric neurons contributed to the IL-6-evoked colonic contractility, this is not 
the case for leptin. Myenteric neurons exhibited strong expression of IL-6Rs but little ObR 
expression. Consistent with this finding, leptin did not evoke calcium responses in myenteric 
neurons. Furthermore, TTX had no effect on leptin-evoked contractile activity in either the 
circular or longitudinal colonic muscle strips, suggesting that the capacity of leptin to suppress 
IL-6-evoked activity may be mediated through its actions on smooth muscle rather than via 
myenteric neurons. 
 
These studies demonstrate that leptin has neuromodulatory effects in submucosal neurons, 
stimulating increases in intracellular calcium via the JAK-STAT signalling pathway. Although 
there was little direct effect of leptin on absorpto-secretory function, it did modify the 
neuronally-mediated stimulatory effects of IL-6. Furthermore, a potentially protective role has 
been identified for leptin in colonic dysmotility, a key symptom of IBS. IL-6, which is elevated 
in IBS, evoked an increase of colonic contractile activity and leptin suppressed this activity. The 
mechanism of this crosstalk between leptin and IL-6 remains to be elucidated but it is likely to be 
through indirect effects, possibly on smooth muscle rather than in the myenteric neurons. These 
studies have demonstrated that leptin can modify the pro-secretory and pro-kinetic effects of IL-
6 on colonic function. Intriguingly, leptin suppressed the neuro-stimulatory effects of IBS 
plasma, which has elevated levels of IL-6, in both submucosal and myenteric neurons, indicating 
a possible role for leptin in ameliorating IBS-associated GI dysfunction.   
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Figure 1: Leptin stimulates submucosal neurons 
A: The representative immunofluorescent images illustrate strong staining of rat submucosal 
neurons with antibodies against IL-6 (red staining) and leptin (green staining) with evidence of 
co-localization (yellow staining) in the merged image.  B: Submucosal neurons also express IL-6 
receptors (IL-6R, green staining) and leptin receptors (ObR, red staining) with evidence of co-
expression (yellow staining, n=3 colons) in the merged image. Scale bar: 200µm C: The dot plot 
and trace illustrate the calcium response to increasing concentrations of leptin and a control 
response to high K+. D: The dot plot and representative trace illustrates activation of the same 
submucosal neurons by both IL-6 and leptin and suppression of the IL-6-evoked response by 
leptin (n=24 neurons). * and *** indicate p<0.05 and p<0.001, respectively. 
 
Figure 2: Leptin-evoked calcium responses in submucosal neurons activate JAK-STAT 
signalling 
A: The dot plot and representative trace demonstrate a large calcium response evoked by leptin 
(1nM, 3min) in submucosal neurons which was reduced by TTX (100nM, 20min, n=34 neurons). 
B: The leptin-evoked calcium response is diminished by the STAT3 inhibitor, WP1006 (WP, 10 
µM, 20min, n=31) although the inhibitory effect of IL-6 on leptin is not further changed by WP 
(n=13). C: The leptin-evoked calcium response is potentiated by the PI 3-kinase inhibitor, 
wortmannin (wort, 10µM, 20 min, n=25). However, potentiation of the leptin-evoked response 
by wort was suppressed by the presence of IL-6. D: The ERK-MAPK inhibitor, PD98059 (PD, 
10µM, 30 min, n=22) has no effect on the leptin-evoked calcium response. The presence of IL-6 
(1nM) suppresses the leptin-evoked response but PD has no additional effect (n=32). * and *** 
indicates p<0.05 and p<0.001, respectively.  
 Figure 3: Colonic absorpto-secretory function is modified by IL-6 but not leptin. 
A: The graph shows the changes in transepithelial resistance (TER) in colonic tissue exposed to 
saline (control), leptin (1nM), IL-6 (1nM) or leptin & IL-6 over the course of an experiment (1.8 
±0.3 hours). TER in the IL-6 and leptin & IL-6 groups is significantly increased when the end of 
the experiment is compared to the start. B: The histogram and representative traces show 
changes in colonic short circuit current (ISC). Basal, unstimulated conditions are labelled control. 
A secretory current was generated by IL-6 (1nM, 15 min) in the absence or presence of leptin 
(1nM, 15 min). Leptin did not stimulate colonic secretion (n=9). C: Veratridine (10µM, 15 min) 
stimulates a large Na+ channel-mediated secretory current which is further enhanced by IL-6 but 
not leptin. The IL-6-evoked potentiation of this current is inhibited by leptin (n=9). D: Carbachol 
(10µM, 15 min) - evoked secretion is enhanced by IL-6 but not leptin. Leptin does not affect the 
IL-6-evoked potentiation of carbachol secretion (n=9). E: The biphasic response to capsaicin 
(1µM, 15 min) wasn’t significantly altered by IL-6, leptin or IL-6 & leptin in these experiments 
(n=9). * and ** indicate p<0.05 and P<0.01, respectively. 
 
Figure 4: Leptin attenuates IL-6-evoked contractile activity. 
A: The representative immunofluorescent images illustrate strong staining of myenteric neurons 
with antibodies against IL-6 receptors (IL-6R, green staining) but weak expression of leptin 
receptors (ObR, red staining) and little co-localization (yellow staining, n=3 colons) in the 
merged image. Scale bar: 20µm. B: The dot plot and trace demonstrate that the IL-6- evoked 
calcium response in myenteric neurons is not significantly changed by leptin. C: The histogram 
of the area under the curve (AUC) in arbitrary units (au) and traces illustrate how leptin (1nM, 
20min) inhibits IL-6 (1nM, 20min)-evoked circular muscle contractile activity in circular and D: 
longitudinal muscle (n=5 colons). E: The histogram and trace illustrates that TTX (100nM, 
20min) does not change the stimulatory effect of leptin on circular muscle or F: longitudinal 
contractile activity (n=5). *, ** and *** indicate p<0.05, p<0.01 and p<0.001, respectively. 
 
Figure 5: Leptin levels are elevated in IBS plasma 
A: The representative immunofluorescence images and histogram illustrates expression of the 
early transgene, cFos in the leptin-expressing submucosal neurons exposed to plasma from HCs 
(n=6 pooled samples, 15 minutes exposure) and IBS patients (n=6 pooled samples from all IBS 
subsets, 15 minutes exposure). B: The dot plot and representative trace illustrates suppression of 
IBS plasma-evoked calcium responses in submucosal neurons by co-application of leptin (n=26). 
C: The dot plot and representative trace illustrates the robust calcium response evoked by IBS 
plasma (1:250 dilution) in myenteric neurons is reduced by co-application of leptin (1nM, 3min, 
n=45). D: The dot plots illustrate the response of submucosal (n=26) and myenteric (n=46) 
neurons to IBS plasma in the presence of either recombinant leptin or anti-leptin antibody 
(xleptin). *, ** and *** indicate p<0.05, p<0.01 and p<0.001, respectively. 
 
